Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials
Top Cited Papers
- 1 August 2006
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 368 (9535), 581-588
- https://doi.org/10.1016/s0140-6736(06)69201-5
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of riskEuropean Heart Journal, 2006
- Angiotensin-Converting–Enzyme Inhibition in Stable Coronary Artery DiseaseNew England Journal of Medicine, 2004
- Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attackThe Lancet, 2001
- Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patientsThe Lancet, 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute m yocardial infarctionThe Lancet, 1999
- Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design)The American Journal of Cardiology, 1998
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection FractionsNew England Journal of Medicine, 1992
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985